Physician profile
Michael N Hakimi
NPI 1912193137
$5,433.96
in general payments reported to CMS, 2019-2025
28 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $348 · 2021: $539 · 2022: $925 · 2023: $1,047 · 2024: $932 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $879.80 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $544.89 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $477.62 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $455.47 | 2023-2025 | Rotapro, Avvigo Guidance System, Watchman Access System |
| Abbott Laboratories | $402.61 | 2019-2025 | Xience Skypoint, Ensite, Xience Sierra |
| Astrazeneca Pharmaceuticals LP | $402.09 | 2019-2025 | Farxiga |
| Amgen INC. | $339.18 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $338.01 | 2021-2025 | Verquvo, Capvaxive |
| Kiniksa Pharmaceuticals, LTD. | $185.23 | 2021-2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $151.37 | 2019-2025 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $147.89 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.27 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $142.36 | 2019-2023 | Xarelto |
| Biotronik INC. | $117.65 | 2019-2025 | Orsiro Mission |
| Kestra Medical Technology Services, INC. | $114.98 | 2022-2023 | Assure Wcd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $92.13 | 2019-2025 | |
| Scpharmaceuticals INC. | $78.59 | 2023-2024 | |
| Medtronic, INC. | $70.23 | 2021-2025 | Reveal Linq, Azure Xt Dr Mri Surescan |
| Abbvie INC. | $54.71 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $53.47 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $47.87 | 2024-2025 | Amvuttra, Onpattro |
| Sanofi-Aventis U.S. LLC | $39.60 | 2023-2024 | |
| Itamar Medical INC | $38.30 | 2022 | |
| Medtronic Vascular, INC. | $29.65 | 2020 | |
| Novo Nordisk INC | $28.54 | 2025 | Wegovy |
| Lantheus Medical Imaging, INC. | $20.91 | 2024 | |
| Cardiovascular Systems INC. | $20.11 | 2021 | |
| Philips North America LLC | $17.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hakimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.